WBB Securities is home to one of the most highly regarded healthcare research franchises operating in the life sciences. WBB Securities’ research team follows emerging and established companies in the biotechnology, specialty pharmaceutical, and medical device sectors. We are driven by the imperative to identify and bring investor attention to the most important, potentially disruptive scientific discovery and development occurring today. Our focus at WBB Securities is constant as we seek to reveal new investment strategies through our research coverage of the life sciences. This is done not only to aid our institutional clients to identify and make smart investments, but to ensure that vital science is continued and supported through our efforts.

WBB Securities’ equity research capability has garnered a reputation for its ability to identify valuable technologies and recommend life science companies for investment. Our team has spent thousands of hours conducting diligence and proprietary modeling on scientific technologies and businesses that have gone on to yield medical breakthroughs. Our equity research is available on the Thomson-Reuters First Call System and FactSet Research. Our analysts have been singled out and distinguished by all of the major ratings agencies for research recommendation performance year after year, garnering our firm a reputation for investing excellence.